Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H12N2.ClH |
Molecular Weight | 244.719 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(C1=NC2=C(N1)C=CC=C2)C3=CC=CC=C3
InChI
InChIKey=CJTQARUHALKPGG-UHFFFAOYSA-N
InChI=1S/C14H12N2.ClH/c1-2-6-11(7-3-1)10-14-15-12-8-4-5-9-13(12)16-14;/h1-9H,10H2,(H,15,16);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H12N2 |
Molecular Weight | 208.2585 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.vidal.ru/drugs/bendazol
Sources: https://www.vidal.ru/drugs/bendazol
Bendazol (or dibazol), a vasodilator that used in Russia. This drug is indicated for the treatment of arterial hypertension, hypertensive crisis, spasms of internal organs (stomach ulcer, intestinal spasms), and diseases of the nervous system: residual effects of poliomyelitis. Bendazol lowers blood pressure by reducing cardiac output and expansion of peripheral vessels.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Bis(2-benzyl-1H-benzimidazole-N3)dichlorozinc(II). | 2001 Jan |
|
Substituent effects on enthalpies of formation of nitrogen heterocycles: 2-substituted benzimidazoles and related compounds. | 2006 Feb 23 |
|
1,3-Bis(1-benzyl-1H-benzimidazol-2-yl)-2-oxapropane. | 2009 Apr 10 |
|
Bis[1,3-bis-(1-benzyl-1H-benzimidazol-2-yl)-2-oxapropane]zinc(II) dipicrate dimethyl-formamide disolvate. | 2009 Jun 17 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.vidal.ru/drugs/bendazol
peripheral facial nerve palsy, polyneuritis.
hypertensive crisis – intravenous or intramuscular: 30-40 mg.
arterial hypertension with a significant increase in blood pressure – intramuscular: 20-30 mg 2-3 times / day, the course: 8-14 days.
nervous diseases: adults: 5 mg 1 time/day
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:28:24 GMT 2023
by
admin
on
Sat Dec 16 01:28:24 GMT 2023
|
Record UNII |
ME751TL810
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m67
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID30153179
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | |||
|
1212-48-2
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | |||
|
214-921-2
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | |||
|
ME751TL810
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | |||
|
164798
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | |||
|
SUB32247
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY | |||
|
100000124523
Created by
admin on Sat Dec 16 01:28:25 GMT 2023 , Edited by admin on Sat Dec 16 01:28:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |